# Subcutaneous Daratumumab Administration in the Thigh Vs Abdomen in Plasma Cell Disorders

> **NCT07075510** · PHASE1,PHASE2 · RECRUITING · sponsor: **University of Maryland, Baltimore** · enrollment: 30 (estimated)

## Conditions studied

- Plasma Cell Disorder

## Interventions

- **DRUG:** Daratumumab Injection

## Key facts

- **NCT ID:** NCT07075510
- **Lead sponsor:** University of Maryland, Baltimore
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-23
- **Primary completion:** 2030-10-01
- **Final completion:** 2032-10-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-10-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07075510

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07075510, "Subcutaneous Daratumumab Administration in the Thigh Vs Abdomen in Plasma Cell Disorders". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07075510. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*